Global Botulinum Toxin Market Size To Reach USD 7.3 Billion By 2025 | Key Industry Players Allergan, Inc. & Ipsen Group

San Francisco, 27 Nov 2018 - The global botulinum toxin (BNT) market is expected to reach a value of USD 7.3 billion by 2025. The constant introduction of innovative products for enhancement of aesthetic appeal supporting minimally invasive aesthetic treatments is the prime factor driving the growth of the market.

In addition, rapid growth of the sector is attributed to the rising demand for minimally invasive or non-invasive procedures. These procedures provide advantages such as small incision, shorter hospital stay and rapid wound healing, and hence lead to larger acceptance and demand. In addition, availability of wide variety of minimally invasive or non-invasive treatment options is pushing the global botulinum toxin market towards growth.

Also, the successful completion of research projects is expected to expand the applications of presently approved products. Companies are trying to widen the application of botulinum toxin in therapeutic area through various research activities. For instance, Botox by Allergan received the U.S. FDA approval for the treatment of strabismus (crossed eyes) and blepharospasm associated with dystonia in 1989. Furthermore, in 2004, Botox was approved by the U.S. FDA for hyperidrosis, cervical dystonia, upper limb spasticity, chronic migraine and urinary incontinence in 2009, 2010 and 2011 respectively. Hence, these factors all together will aid in boosting the growth of BNT sales during the forecast period.

To request a sample copy or view summary of this report, click the link below: www.grandviewresearch.com/industry-analysis/botulinum-toxin-market

Further Key Findings from the Study Suggest:

• The rapid adoption of minimally invasive treatment is augmenting the growth of neurotoxins market.
• The botulinum toxin type A segment accounted for the largest share in 2015 and is also anticipated to be the fastest growing segment during the forecast period
• In 2015, North America dominated the global space with the largest revenue share owing to high demand for minimally invasive or non-invasive aesthetic treatments
• Asia Pacific is expected to emerge as the fastest growing region during the forecast period, mainly due to growing social awareness regarding anti-wrinkle procedures in India, China, and Japan
• Major players competing in this market include but are not limited to Allergan, Inc.; Ipsen Group; Merz GmbH and Co. KGaA, Medytox,Inc.; US Worldmed, LLC; Lanzhou Institute of Biological Products. Co.Ltd. and Revance Therapeutics, Inc.

Access More Reports Of The Same Category: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the botulinum toxin market by type, end use, and region:

Product Type Outlook (Revenue, USD Million; 2013 - 2025)

• Botulinum Toxin Type A
• Botulinum Toxin Type B

End Use Outlook (Revenue, USD Million; 2013 - 2025)

• Therapeutic
• Aesthetic

Regional Outlook (Revenue, USD Million; 2013 - 2025)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK
• Asia Pacific
  • China
  • Japan
• Latin America
  • Mexico
  • Brazil
• MEA
  • South Africa

Browse Press Release of this Report: www.grandviewresearch.com/press-release/global-botulinum-toxin-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Gastrointestinal Therapeutics Market Size Worth $65.1 Billion By 2025 | Key Industry Participants Abbott Laboratories, Allergan PLC.

San Francisco, 23 October 2018 - According to a report published by Grand View Research, Inc.; the gastrointestinal therapeutics market is expected to reach a valuation of around USD 65.1 billion by 2025. Rise in cases of gastrointestinal diseases and growing use of adoption of biologics for treatment of gastrointestinal diseases can propel the market during the forecast period (2014 to 2025).

Rising geriatric population susceptible to gastrointestinal complaints is a major driving factor for the market. In 2014, colon cancer caused approximately 694,000 deaths, as per statistics provided by WHO. So, increasing efforts by the Centers for Disease Control and Prevention (CDC) to encourage cancer screening across the nation is expected to propel the market. Also, the Division of Cancer Prevention and Control (DCPC) supports National Colorectal Cancer Action Campaign (NCCCP) as well as provides funding to help research studies and execute approaches to control colorectal cancer. This surge in screening efforts is anticipated to increase sales of therapeutics and create more opportunities in the market. Moreover, burgeoning demand for reducing cost of drug development along with administration costs is expected to create growth opportunities for biologics. In addition, development of targeted treatment options has encouraged development of personalized biologics, which is expected to bode well for the market.

Access Full Insights Report On Gastrointestinal Therapeutics Market: www.grandviewresearch.com/industry-analysis/gastrointestinal-therapeutics-market

Worldwide gastrointestinal therapeutics market can be segmented on the basis of type, route of administration, application, distribution channel, and region.

Based on type, the market can be classified into branded and generics. In 2016, the branded segment estimated for the largest share. But, segment is expected to reduce its growth due to increasing sales of generics. Generics segment are likely to grow at a lucrative CAGR due to their high cost-efficiency, increasing number of patent expirations, and increasing efforts from government organizations to encourage the use of these drugs in developing countries. Increasing efforts from pharmaceutical companies to develop and launch these drugs due to patent expiration of their branded drugs is expected to support the market growth. As per route of administration, the market can be split into intravenous, oral, and others. The intravenous segment estimated for the major share in 2016 due to benefits associated with IV products. In 2016, oral products segment estimated for the second-largest share due to its high efficacy. But, other route such as intravenous and transdermal consist better bioavailability as compared to oral products, which lead to decline in its use. Additionally, these products are not convenient for patients in younger age groups.

As per application, the market can be split into ulcerative colitis, Crohn’s disease, GERD, and others. The Crohn’s disease segment is expected to show a lucrative gain during the forecast period due to growing prevalence of chronic diseases like cancer and diabetes. On the basis of distribution channel, the market can be bifurcated into retail pharmacies, hospital pharmacies, and online pharmacies. 

Geographically, the market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

In 2016, North America market estimated for the major market share and likely to follow same trend over the projected period. This growth can be associated with chaining lifestyle lead to gastrointestinal diseases, supportive government efforts for prevention and treating gastrointestinal diseases. For instance, the Integrated Global Action Plan for Diarrhea initiated by WHO and UNICEF to control childhood deaths caused due to diarrhea by spreading awareness and providing treatment and preventive measures. Around 1.3 million people are suffering from Inflammatory Bowel Disease (IBD) in U.S., as per estimated by the Centers for Disease Control and Prevention (CDC).

Asia Pacific is expected to be the fastest growing market due to increasing efforts by the major market participants, which include R&D and commercialization of branded drugs at comparatively less price. Additionally, growing development of healthcare infrastructure and increasing need to control occurrence of gastrointestinal disorders can drive the regional market.

Prominent players operating in the market include AbbVie, Inc.; Allergan plc; Valeant Pharmaceuticals; Takeda Pharmaceuticals; and Pfizer.

Access More Reports Of The Same Category: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global gastrointestinal therapeutics market on the basis of type, route of administration, application, distribution channel, and region:

Gastrointestinal Therapeutics Type Outlook (Revenue, USD Million, 2014 - 2025)

• Branded
  • Aminosalicylates
  • Antacids
  • Enzyme Replacement Therapies
  • Proton Pump Inhibitors
  • Laxatives
  • Antiemetics
  • H2 Antagonists
  • Antidiarrheals
  • Biologics
  • Others
• Generics

Gastrointestinal Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

• Oral
• Intravenous
• Others

Gastrointestinal Therapeutics Application Outlook (Revenue, USD Million, 2014 - 2025)

• Ulcerative Colitis
• Crohn’s Disease
• GERD
• Others

Gastrointestinal Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2014 - 2025)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Gastrointestinal Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Browse Press Release of this Report: www.grandviewresearch.com/press-release/global-gastrointestinal-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com